shelf(0)

No. 005 · Repair · Anti-Inflammatory

KPV

Lys-Pro-Valα-MSH (11-13)

C Tier C · Animal data how tiers work →
  • Not FDA approved
  • WADA ✗ S0
Compare Cite
Fingerprint no sequence
KPV (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Quick answers

What is KPV?
A tripeptide fragment of alpha-MSH with potent anti-inflammatory and antimicrobial activity.
How strong is the evidence for KPV?
Tier C (animal data) on the peptidemeta evidence scale. Only cell and animal (mainly colitis model) studies are published; no completed human trials.
Is KPV FDA-approved?
No. KPV is not approved by the FDA for any use.
Is KPV banned in sport?
Yes. KPV is prohibited in sport by the World Anti-Doping Agency under S0 (non-approved substances).
How does KPV work?
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH that enters cells and directly inhibits NF-kB nuclear translocation by preventing IkB-alpha phosphorylation. This blocks transcription of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and reduces intestinal and systemic inflammation.
What is known about the safety of KPV?
Limited formal human safety data. Preclinical studies show good tolerability.

Last reviewed · editorial policy · markdown

02

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER C — Evidence comes mostly from animal studies.

Only cell and animal (mainly colitis model) studies are published; no completed human trials.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

03

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved
WADA
Prohibited · S0 Non-approved substances
04

Overview

A tripeptide fragment of alpha-MSH with potent anti-inflammatory and antimicrobial activity. It modulates NF-kB signaling and is explored for gut and skin inflammation.

Research status Preclinical studies in inflammatory bowel models; emerging human anecdotal data

05

Mechanism

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH that enters cells and directly inhibits NF-kB nuclear translocation by preventing IkB-alpha phosphorylation. This blocks transcription of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and reduces intestinal and systemic inflammation.

06

Effects reported in research

Reported outcomes, not promises. These come mostly from preclinical (cell or animal) research and have not been confirmed in human trials.

  • Reduced intestinal inflammation
  • Modulated immune response via NF-kB inhibition
  • Antimicrobial activity against pathogens
  • Improved skin inflammatory conditions
07

Safety & unknowns

Limited formal human safety data. Preclinical studies show good tolerability. As a fragment of endogenous alpha-MSH, it is expected to have a favorable safety profile. Not FDA-approved.

Unknowns. No randomized controlled trials in humans have been published, so human safety has not been established in controlled studies.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

08

Studies [0]

No studies cited for this entry yet.

10

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

11

Cite this entry

$ cite --format=apa

peptidemeta. (2026). KPV. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/kpv/

$ cite --format=bibtex 
@misc{peptidemeta-kpv,
  title = {KPV},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/kpv/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open